Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Leadership and Governance Structure
URGN logo

UroGen Pharma Aligns Leadership Pay to $675M Oncology Milestones

URGN10-KFiling Date: 4/30/2025
UroGen Pharma Ltd.
Description

What this story covers

UroGen Pharma's 10-K amendment details robust governance with an expert board, performance-tied compensation emphasizing equity for pipeline advances like UGN-102, arm's-length transactions, balanced ownership, and low-risk policies with PwC audits ensuring transparency in urologic cancer therapies.

Story snapshot

CompanyUroGen Pharma Ltd.
TickerURGN
VariantStandard detailed
Duration11:14
Filing type10-K
PeriodAnnual 2024
IndustryHealthcare & Pharmaceuticals
Accession0001437749-25-013839

Full Story Script

Content not available for this story.

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in